Aquinnah Pharmaceuticals

About

Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke

Cambridge,Massachusetts,United States
11 - 50
http://aquinnahpharma.com

Highlights

Details

Last Funding Type: Series Unknown
Last Funding Money Raised: $5M
Industries: Health Care,Hospital,Medical,Pharmaceutical
Founded date: Jan 1, 2006
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Aquinnah Pharmaceuticals Inc.

Aquinnah Pharmaceuticals is focused on an exciting new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

$19.83M

Aquinnah Pharmaceuticals has raised a total of $19.83M in funding over 2 rounds. Their latest funding was raised on Jan 17, 2019 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 17, 2019	Grant	$750K	2	Alzheimer's Association	—	Detail
Jun 21, 2018	Grant	$3.40M	1	National Institutes of Health	—	Detail
Apr 25, 2017	Series Unknown	$10M	2	Pfizer AbbVie	—	Detail
Dec 21, 2015	Series Unknown	$5M	1	Takeda	—	Detail
Nov 23, 2015	Grant	$680K	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

6

Aquinnah Pharmaceuticals is funded by 6 investors. Alzheimer's Association and National Institutes of Health are the most recent investors.

Investor Name	Lead Investor	Funding Round
Alzheimer's Association	Yes	Grant
National Institutes of Health	Yes	Grant
Pfizer	Yes	Series Unknown
AbbVie	Yes	Series Unknown
Takeda	Yes	Series Unknown
Tau Consortium	—	Grant